Results 181 to 190 of about 101,340 (329)
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. [PDF]
Chin Neurosurg J, 2022 Cai X +5 more
europepmc +1 more source
Dopamine agonists: their role in the treatment of Parkinson's disease [PDF]
, 2000 David J. Brooks
openalex +1 more source
Movement Disorders, EarlyView.Abstract Background Differentiating progressive supranuclear palsy (PSP) from other parkinsonian disorders may be challenging. Objectives To investigate the role of transforming growth factor beta‐1 (TGFβ1) in PSP. Methods A total of 33 PSP, 39 Parkinson's disease (PD), 8 multiple system atrophy (MSA) patients, and 50 healthy controls (HC) were ...
Selena Mimmi +16 more
wiley +1 more source
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. [PDF]
Front Endocrinol (Lausanne), 2021 Tang H +5 more
europepmc +1 more source
Fenoldopam, a Dopamine Agonist, for Hypertensive Emergency: A Multicenter Randomized Trial [PDF]
, 2000 James A. Tumlin +9 more
openalex +1 more source
Movement Disorders, EarlyView.ABSTRACT Neuroimaging with positron emission tomography (PET) has been instrumental in elucidating neurobiological mechanisms behind therapeutical trials in Parkinson's disease (PD). A variety of medical and neurosurgical interventions have been evaluated using many radioligands that reveal molecular basis for target engagement and brain responses in ...
Vijay Dhawan +4 more
wiley +1 more source
Super-stereotypy II: Enhancement of a complex movement sequence by intraventricular dopamine D1 agonists [PDF]
, 2000 Kent Berridge, J. Wayne Aldridge
openalex +1 more source